Teva prices Sfr450m Swiss franc debut at tightened guidance
Teva Pharmaceutical Industries, the Israeli generic drug company, issued a Sfr450m debut Swiss franc bond on Monday at 80bp over mid-swaps.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts